- Home
- NBH vs AQST Comparison
NBH vs AQST Comparison
Compare NBH & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- AQST
- Stock Information
- Founded
- NBH 2002
- AQST 2004
- Country
- NBH United States
- AQST United States
- Employees
- NBH N/A
- AQST N/A
- Industry
- NBH Finance/Investors Services
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- NBH Finance
- AQST Health Care
- Exchange
- NBH Nasdaq
- AQST Nasdaq
- Market Cap
- NBH 291.1M
- AQST 254.1M
- IPO Year
- NBH N/A
- AQST 2018
- Fundamental
- Price
- NBH $9.85
- AQST $2.51
- Analyst Decision
- NBH
- AQST Strong Buy
- Analyst Count
- NBH 0
- AQST 6
- Target Price
- NBH N/A
- AQST $11.17
- AVG Volume (30 Days)
- NBH 85.9K
- AQST 1.4M
- Earning Date
- NBH 01-01-0001
- AQST 05-06-2025
- Dividend Yield
- NBH 4.34%
- AQST N/A
- EPS Growth
- NBH N/A
- AQST N/A
- EPS
- NBH 0.12
- AQST N/A
- Revenue
- NBH N/A
- AQST $57,561,000.00
- Revenue This Year
- NBH N/A
- AQST N/A
- Revenue Next Year
- NBH N/A
- AQST $39.51
- P/E Ratio
- NBH $87.04
- AQST N/A
- Revenue Growth
- NBH N/A
- AQST 13.79
- 52 Week Low
- NBH $8.75
- AQST $2.20
- 52 Week High
- NBH $11.01
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- NBH 35.83
- AQST 41.88
- Support Level
- NBH $9.80
- AQST $2.20
- Resistance Level
- NBH $9.98
- AQST $2.61
- Average True Range (ATR)
- NBH 0.19
- AQST 0.22
- MACD
- NBH -0.03
- AQST -0.03
- Stochastic Oscillator
- NBH 36.19
- AQST 36.47
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.